Health & Nutrition
CDC asks all staff to return to office Sept. 15, five weeks...
The internal announcement comes at a tumultuous time for the CDC and its workforce,...
Amgen to invest $600 million in new research and development...
It is the latest U.S. investment by a drugmaker as President Donald Trump threatens...
Trump tells drugmakers to 'justify the success' of Covid...
Health and Human Services Secretary Robert F. Kennedy Jr. has taken measures to...
Healthy Returns: Novo Nordisk’s head of research and development...
Novo Nordisk's Martin Holst Lange preveiwed the company's obesity pill, while OpenAI...
Florida to become first state to end all vaccine mandates,...
The move would make Florida the first U.S. state to withdraw from mandates credited...
Dietary Diversity and Overeating
Big Food uses our hard-wired drive for dietary diversity against us. How did we...
Taking Advantage of Sensory-Specific Satiety
How can we use sensory-specific satiety to our advantage? When we eat the same foods...
A world on weight loss drugs: How GLP-1s are reshaping...
As GLP-1 adoption grows and new applications for the drugs come to light, experts...
Eli Lilly's obesity pill remains a viable rival to Novo's...
Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk,...
Eli Lilly’s weight loss pill orforglipron clears its latest...
Eli Lilly now has the clinical trial data required to start filing for approvals...